List of Excipients in Branded Drug ZONALON

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mylan Pharmaceuticals Inc	ZONALON	doxepin hydrochloride	0378-8123	BENZYL ALCOHOL
Mylan Pharmaceuticals Inc	ZONALON	doxepin hydrochloride	0378-8123	CETYL ALCOHOL
Mylan Pharmaceuticals Inc	ZONALON	doxepin hydrochloride	0378-8123	ISOPROPYL MYRISTATE
Mylan Pharmaceuticals Inc	ZONALON	doxepin hydrochloride	0378-8123	PEG-10 GLYCERYL STEARATE
Mylan Pharmaceuticals Inc	ZONALON	doxepin hydrochloride	0378-8123	PEG-100 STEARATE
Mylan Pharmaceuticals Inc	ZONALON	doxepin hydrochloride	0378-8123	PETROLATUM

Zonalon Excipient Strategy and Commercial Opportunities for Doxepin 5% Cream

Last updated: August 24, 2026

Zonalon is a topical doxepin hydrochloride 5% cream used for short-term treatment of moderate pruritus in adults and children 12 years and older. Its commercial opportunity is constrained by doxepin’s systemic absorption and sedative warnings, but the product remains suitable for formulation differentiation in barrier repair, skin tolerability, delivery control, packaging, and generic substitution. The strongest opportunities are lower-absorption formulations, improved cosmetic properties, preservative and allergen reduction, and products that support chronic itch management without materially changing the approved pharmacology.

What is Zonalon and how does its formulation work?

Zonalon contains doxepin hydrochloride at a concentration equivalent to 5% doxepin in a topical cream base. Doxepin is a tricyclic compound with antihistaminic and anticholinergic activity. Zonalon is indicated for moderate pruritus associated with atopic dermatitis or lichen simplex chronicus and is generally applied four times daily for up to eight days.[1]

The commercial formulation is an oil-in-water cream containing conventional emollient, surfactant, fatty alcohol, and mineral-oil components. Public labeling identifies inactive ingredients including cetyl alcohol, isopropyl myristate, light mineral oil, polysorbate 60, purified water, sorbitan monostearate, and stearyl alcohol.[1]

Product attribute	Zonalon profile
Active ingredient	Doxepin hydrochloride
Strength	5% cream
Dosage form	Topical semisolid cream
FDA application	NDA 019941
Indication	Moderate pruritus associated with atopic dermatitis or lichen simplex chronicus
Age threshold	Adults and pediatric patients 12 years and older
Dosing	Four times daily for up to eight days
Key safety issue	Systemic absorption with drowsiness, sedation, and anticholinergic effects
Major formulation constraint	Broad application or prolonged use can increase systemic exposure
Reference product	Zonalon cream

Zonalon’s label warns against use over large areas and identifies drowsiness as a clinically relevant adverse effect. The label also warns that alcohol and other central nervous system depressants may increase sedation.[1]

What excipients are used in Zonalon cream?

The Zonalon excipient system is designed to create a spreadable, occlusive cream rather than a highly penetrating transdermal vehicle.

Functional role of the principal excipients

Excipient	Likely formulation function	Commercial relevance
Light mineral oil	Emollient and occlusive oil phase	Supports moisturization and reduces transepidermal water loss
Isopropyl myristate	Emollient and spreading agent	Improves glide but can increase penetration and may be unsuitable for acne-prone or sensitive skin
Cetyl alcohol	Thickener, emollient, and consistency agent	Supports cream structure and sensory profile
Stearyl alcohol	Co-emulsifier and viscosity modifier	Provides body and improves stability
Polysorbate 60	Nonionic emulsifier	Stabilizes the oil-in-water emulsion
Sorbitan monostearate	Lipophilic co-emulsifier	Works with polysorbate 60 to maintain emulsion stability
Purified water	Continuous phase	Controls viscosity, evaporation, and application feel

The formulation uses a conventional paired-emulsifier system. Polysorbate 60 supplies hydrophilic emulsification, while sorbitan monostearate contributes lipophilic stabilization. Cetyl and stearyl alcohols create a structured lamellar cream network that controls viscosity and skin feel.

This architecture is commercially familiar but leaves room for improvement. The principal development challenge is balancing four variables:

1. Sufficient skin deposition of doxepin.
2. Low systemic absorption.
3. Acceptable spreadability and patient adherence.
4. Physical and chemical stability during shelf life.

What excipient strategies could improve Zonalon?

The highest-value strategies do not seek maximum dermal penetration. They seek controlled epidermal delivery while limiting systemic exposure.

1. Reduce penetration-enhancing excipients

Isopropyl myristate can improve spreading and may influence skin permeation. A reformulated product could replace or reduce it with less penetration-promoting emollients such as selected medium-chain triglycerides, hydrogenated polyisobutene, hemisqualane, or carefully chosen ester oils.

The commercial objective would be a narrower exposure profile:

• adequate local drug deposition;
• reduced flux through viable skin;
• lower risk of drowsiness;
• improved suitability for larger treatment areas.

A lower-penetration formulation would require comparative permeation and local deposition work. A change that reduces systemic exposure but also reduces local efficacy may not support an ANDA or a simple line extension without additional clinical evidence.

2. Develop a barrier-supportive vehicle

Atopic dermatitis and lichen simplex chronicus involve impaired barrier function and irritation. A cream incorporating barrier-supportive lipids could improve the product’s clinical positioning, although the active ingredient would remain doxepin.

Candidate excipient systems include:

• ceramide-containing lipid blends;
• cholesterol and free-fatty-acid systems;
• glycerol or propylene glycol humectant systems;
• colloidal oatmeal;
• dimethicone or other protective silicones;
• nonionic, low-irritancy emulsifier systems.

A barrier-supportive formulation could target patients who need antipruritic therapy plus moisturization. The main limitation is regulatory classification. Adding a recognized skin protectant, such as colloidal oatmeal or dimethicone at an OTC monograph level, could complicate labeling and require a separate commercial strategy rather than a straightforward Zonalon generic.

3. Improve cosmetic acceptability

Topical adherence is often affected by residue, greasiness, tack, whitening, and slow absorption. Zonalon’s mineral-oil and fatty-alcohol base can be modified to produce:

• faster rub-in;
• lower tack;
• reduced greasy residue;
• better compatibility with clothing;
• improved use on hair-bearing skin;
• lower transfer from treated skin to bedding or garments.

The most commercially practical approach is a modernized cream or light emulsion that preserves the same concentration and route of administration. A lotion, gel-cream, or emulgel could offer differentiation, but the farther the product moves from the reference cream, the greater the bioequivalence and regulatory burden.

4. Pursue preservative-minimized or preservative-free packaging

The publicly listed Zonalon excipients do not identify a conventional antimicrobial preservative.[1] That creates a potential positioning advantage for sensitive-skin patients. A reformulator should preserve this characteristic where feasible.

Commercial options include:

• airless pump packaging;
• unit-dose sachets;
• laminated tubes with low oxygen and low moisture transmission;
• smaller pack sizes to reduce repeated contamination;
• validated in-use microbiological controls.

Packaging can be a meaningful product differentiator when the formula itself is difficult to alter without affecting bioequivalence. The patent opportunity may reside in the combination of cream composition, container closure, dosing system, and microbial-control method.

5. Control application and reduce misuse

Zonalon is labeled for limited-duration treatment. A metered-dose pump, calibrated applicator, or unit-dose package could help limit excessive application and improve adherence to the eight-day treatment period.

Potential advantages include:

• more consistent dose per application;
• reduced application to large body areas;
• better patient instructions;
• lower risk of accidental exposure to children;
• improved pharmacy and payer differentiation.

A delivery device would need to demonstrate dose uniformity, container compatibility, stability, and reliable performance throughout product use.

What formulation patents could protect a Zonalon follow-on product?

The original Zonalon formulation is unlikely to provide a significant current exclusivity barrier because the product was approved decades ago and doxepin is a long-established active ingredient. The commercial value would come from new formulation or delivery claims.

Potential claim categories

Claim category	Example subject matter	Expected strategic value
Composition	Doxepin 5% with a defined emollient, emulsifier, humectant, or lipid ratio	Moderate to high if the formulation produces measurable performance advantages
Reduced systemic exposure	Formulation producing lower plasma exposure than Zonalon	High, but difficult to prove and enforce
Skin deposition	Defined in vitro or ex vivo deposition profile	Moderate
Dosage form	Emulgel, lotion, foam, spray, or anhydrous cream	Moderate
Packaging	Metered pump, airless container, or unit-dose package	Moderate
Stability	Reduced degradation or improved physical stability	Low to moderate unless technically unexpected
Manufacturing process	Controlled homogenization, particle-size distribution, or thermal processing	Moderate
Method of use	Application to a defined body surface or limited-duration regimen	Moderate, with possible enforceability limitations
Combination therapy	Doxepin with barrier-repair or anti-inflammatory excipients	Moderate, but clinical differentiation may be required

A strong patent estate would combine composition claims with performance-based claims, manufacturing claims, and packaging claims. A single broad cream claim is more vulnerable to design-around by generic manufacturers.

When does Zonalon lose exclusivity?

Zonalon’s principal market protections are historical rather than forward-looking. Doxepin hydrochloride is an old active ingredient, and the reference product has been commercially available for many years.

FDA exclusivity and Orange Book considerations

Protection	Zonalon assessment
New chemical entity exclusivity	Expired
Five-year NCE exclusivity	Not applicable to a legacy product currently
Three-year clinical investigation exclusivity	No current basis identified from the legacy approval
Pediatric exclusivity	No current exclusivity identified
Orphan exclusivity	Not applicable
Active Orange Book patent barrier	No current patent barrier should be assumed without a live Orange Book review
Generic pathway	ANDA pathway is commercially plausible
Biosimilar pathway	Not applicable because doxepin is a small molecule

The relevant practical question is not when Zonalon will lose exclusivity. It is whether a generic applicant can obtain approval for doxepin hydrochloride cream while matching the reference product’s pharmaceutical and clinical performance.

The FDA Orange Book should be checked for the current patent listing and exclusivity status before any filing, litigation, or valuation decision.[2] Legacy topical products can have limited listed-patent protection even when formulation know-how remains commercially relevant.

What generic entry risks exist for Zonalon?

The primary generic threat is an ANDA for doxepin hydrochloride cream 5%. A generic applicant would likely target pharmaceutical equivalence to Zonalon and seek approval using the reference product’s established safety and efficacy record.

Likely generic launch scenarios

Scenario	Commercial effect
One approved generic	Moderate price pressure and pharmacy substitution
Multiple ANDA approvals	Rapid erosion in average selling price
Authorized generic	Faster brand-price compression if marketed by the NDA holder
Differentiated follow-on cream	Less direct price competition but higher development cost
505(b)(2) lotion or gel	Potential premium positioning, with greater clinical and regulatory burden
Formulation patent covering a new product	Delayed substitution for the protected product, not necessarily for legacy Zonalon

A Paragraph IV challenge would be relevant only if an ANDA applicant certifies that a listed patent is invalid, unenforceable, or not infringed. If no unexpired patent is listed in the Orange Book, the applicant may avoid a Paragraph IV dispute and proceed through the applicable statutory pathway.[2,3]

For a legacy topical product, the larger practical barrier may be bioequivalence rather than patent litigation. FDA topical semisolid products can present challenges involving formulation sameness, rheology, particle or droplet size, viscosity, release rate, and skin permeation.[3]

How does Zonalon compare with other antipruritic products?

Zonalon occupies a narrow position between prescription antipruritics and nonprescription skin-protectant products.

Product class	Representative products	Main advantage	Main limitation
Topical doxepin	Zonalon	Prescription antihistaminic activity in a topical vehicle	Sedation and systemic absorption
Topical corticosteroids	Hydrocortisone, triamcinolone, other steroids	Strong anti-inflammatory activity	Skin atrophy and other steroid-related risks with overuse
Topical antihistamines	Diphenhydramine products	OTC access	Sensitization and limited chronic-use utility
Pramoxine products	OTC antipruritic creams and lotions	Local anesthetic effect and broad availability	Shorter symptomatic effect in some patients
Menthol or camphor products	OTC cooling formulations	Rapid sensory relief	Temporary effect and irritation in some users
Barrier creams	Dimethicone, petrolatum, colloidal oatmeal	Low-risk moisturization and protection	Do not directly provide prescription antipruritic activity
Topical calcineurin inhibitors	Tacrolimus, pimecrolimus	Steroid-sparing anti-inflammatory treatment	Burning, prescription restrictions, and different indication profile

Zonalon’s commercial weakness is systemic exposure. Its commercial opportunity is a topical prescription mechanism that can provide itch relief without the long-term steroid concerns associated with chronic corticosteroid use.

What licensing and commercial opportunities exist?

The most credible licensing opportunities involve formulation technology rather than the legacy Zonalon brand itself.

Formulation technology licensing

A technology owner could license:

• low-flux emulsion systems;
• skin-deposition enhancers with limited systemic permeation;
• barrier-repair excipient platforms;
• airless and metered topical packaging;
• preservative-free multidose packaging;
• continuous manufacturing or high-shear emulsification methods.

A license should define whether the technology covers doxepin specifically, topical tricyclic compounds generally, or a broader dermatology platform. Broad platform language can improve strategic value but may be harder to defend against prior art.

Brand extension

Potential extensions include:

• a lower-residue cream;
• a once- or twice-daily formulation, if clinically supported;
• a lower-strength product for sensitive skin;
• a lotion or emulgel for hair-bearing areas;
• a pediatric-focused package for patients 12 years and older;
• a barrier-supportive combination product.

A lower strength could reduce exposure but may also reduce efficacy. A reduced-frequency product could improve adherence but would require clinical support because the current label specifies application four times daily for up to eight days.[1]

Generic manufacturer opportunity

Generic manufacturers can compete through:

• early ANDA filing;
• low-cost reference-matched cream;
• preservative-free or sensitive-skin positioning;
• improved packaging;
• authorized-generic supply arrangements;
• contract manufacturing for private-label dermatology products.

The lowest-risk pathway is a conventional cream designed to match Zonalon. The highest-margin pathway is a differentiated 505(b)(2) product with a defensible formulation or delivery advantage.

How strong is the patent estate for Zonalon?

The legacy patent estate is likely weak as a current exclusivity tool because the active ingredient and original product date back several decades. The stronger patent opportunity lies in newly developed compositions and delivery systems.

Patent-strength assessment

Estate component	Assessment
Doxepin composition-of-matter patents	Commercially exhausted
Original cream formulation patents	Likely expired or commercially weak
Current Orange Book blocking patents	Must be verified in the live FDA listing
New low-absorption formulation	Potentially strong if supported by comparative data
Packaging and dosing system	Moderate, especially when integrated with formulation claims
Method-of-use claims	Moderate but vulnerable to label and enforcement issues
Manufacturing claims	Moderate if process parameters produce reproducible product attributes
Trade secrets	Potentially meaningful for scale-up, emulsion control, and filling

The best protection strategy is a layered portfolio filed before broad disclosure. Comparative data should show a measurable advantage over Zonalon, such as lower plasma exposure, improved skin retention, better release control, or superior stability.

What FDA regulatory status applies to new Zonalon formulations?

A conventional doxepin hydrochloride 5% cream that matches Zonalon may be eligible for an ANDA. A materially different dosage form, strength, dosing schedule, or clinical claim may require a 505(b)(2) application.

Regulatory route comparison

Development objective	Likely FDA route
Same active, strength, route, and comparable cream	ANDA
New excipients with reference-product differences	ANDA or 505(b)(2), depending on sameness and evidence
New lotion, foam, gel, or spray	Often 505(b)(2)
New strength	Often 505(b)(2)
New dosing frequency	505(b)(2) with clinical support
New combination with another active	505(b)(2) or separate combination-product pathway
OTC switch	Separate regulatory program with substantial safety and labeling requirements

Excipient selection should begin with FDA Inactive Ingredient Database precedent, dermatologic tolerability, compendial quality, supplier qualification, and extractables and leachables assessment. The formulation must also address microbiological quality, rheology, phase separation, drug content uniformity, in vitro release, and container compatibility.[3,4]

Key Takeaways

• Zonalon is a doxepin hydrochloride 5% prescription cream for short-term treatment of moderate pruritus.
• Its core commercial limitation is systemic doxepin absorption and associated sedation.
• The most attractive excipient strategy is controlled local delivery with lower systemic flux.
• Barrier-supportive lipids, low-irritancy emulsifiers, modern emollients, and improved packaging offer practical differentiation.
• A matched generic cream is likely to compete primarily on price.
• A materially different lotion, gel, foam, strength, or dosing regimen would likely require a 505(b)(2) strategy.
• The original Zonalon patent position is unlikely to provide a substantial current barrier; new formulation, packaging, manufacturing, and performance claims are more relevant.
• Biosimilar risk does not apply because doxepin is a small-molecule drug.
• A live Orange Book review is required before relying on any current patent or Paragraph IV conclusion.

FAQs

Can a preservative-free doxepin cream compete with Zonalon?

Yes. A preservative-free or preservative-minimized product could target sensitive-skin patients, but packaging and in-use microbiological controls must support the product throughout its labeled use period.

Is isopropyl myristate a good excipient for a next-generation doxepin cream?

It can improve spreadability, but its potential effect on skin permeation makes it unsuitable for a formulation whose main objective is reduced systemic absorption unless comparative permeation data support its use.

Could Zonalon be reformulated as a foam?

Potentially, but a foam would likely have different release, evaporation, dosing, and skin-deposition characteristics. The regulatory program would probably require more than a simple reference-matched ANDA approach.

Does a new doxepin cream automatically receive new market exclusivity?

No. A new formulation must satisfy statutory requirements for an applicable exclusivity period. Patent protection and FDA regulatory exclusivity are separate rights.

What is the most defensible patent claim for a follow-on doxepin topical?

A claim combining a defined excipient system with demonstrated lower systemic exposure, controlled skin deposition, or a reproducible release profile is generally more defensible than a broad claim covering doxepin in any topical cream.

References

1. U.S. Food and Drug Administration. (n.d.). Zonalon (doxepin hydrochloride) cream, 5% prescribing information. DailyMed, National Library of Medicine.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2022). Product-specific guidance for doxepin hydrochloride topical cream. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2019). Draft guidance for industry: Nonsterile semisolid dosage forms: Scale-up and postapproval changes. U.S. Department of Health and Human Services.